↓ Skip to main content
What is this page? Embed badge

Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report

Overview of attention for article published in Anais Brasileiros de Dermatologia, January 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
18 Mendeley
Summary Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
Published in
Anais Brasileiros de Dermatologia, January 2014
DOI 10.1590/abd1806-4841.20142887
Pubmed ID
24626663
Authors

Clarissa Luiza Dalla Bernardina Carvalho, Luciena Cegatto Martins Ortigosa

Abstract

The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 6%
Unknown 17 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 22%
Student > Bachelor 2 11%
Unspecified 2 11%
Student > Postgraduate 2 11%
Researcher 2 11%
Other 5 28%
Unknown 1 6%
Readers by discipline Count As %
Medicine and Dentistry 5 28%
Pharmacology, Toxicology and Pharmaceutical Science 2 11%
Agricultural and Biological Sciences 2 11%
Unspecified 2 11%
Immunology and Microbiology 2 11%
Other 4 22%
Unknown 1 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2014.
All research outputs
#15,298,293
of 22,751,628 outputs
Outputs from Anais Brasileiros de Dermatologia
#429
of 891 outputs
Outputs of similar age
#189,995
of 305,229 outputs
Outputs of similar age from Anais Brasileiros de Dermatologia
#26
of 51 outputs
Altmetric has tracked 22,751,628 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 891 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,229 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.